This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment option.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

Injection site reactions, such as bleeding or pain, were common side effects of Zepbound. These reactions should go away on their own within a few days of injecting your Zepbound dose. But ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Zepbound's side effects can include nausea, diarrhea, vomiting, constipation, stomach discomfort and pain. Other side effects include fatigue, allergic reactions, burping, hair loss and ...

Indianapolis: Eli Lilly and Company has announced the U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) as a prescription medicine for adults with ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Zepbound-treated patients also reported a significant decrease in body weight, the FDA mentioned. The drug can reportedly cause side effects like ... of medullary thyroid cancer or with multiple ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...